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Objective: To explore the clinical and financial impact of hospital-acquired infections 
(HAIs) in patients admitted to the Intensive Care Unit (ICU) using statewide 
representative databases for Washington (WA), New Jersey (NJ), Florida (FL) and New 
York (NY). Specifically, the following questions will be addressed: 1) Is there an 
association between HAIs and hospital Length of Stay (LOS) in patients who have an 
ICU stay?, 2) Is there an association between HAIs and hospital mortality in patients who 
have an ICU stay?, 3) Is there an association between HAIs and hospital cost in patients 
who have an ICU stay?, 4) Does the association of HAIs to LOS, mortality and costs vary 
by type of HAI (as identified by diagnosis related codes) in patients who have ICU stay?, 
and 5) Does the association of HAIs to LOS, mortality and cost vary by sex (male or 
female) in patients who have ICU stay? 
Methods: Multi-state hospital billing data retrospective cohort study using Healthcare Cost 




Results: HAIs have significant association to clinical and financial indicators within the 
ICU: LOS increases by a factor of 2.49 times (22.94 days vs. 9.20 days), mortality 
increases by a factor of 7.149 times, and total adjusted cost increases by a factor of 3.02 
times ($68,503 vs. $22,659). 
Discussion: Certain states such as WA report higher HAI infection rates than others (NY, 
NJ and FL). It needs to be determined if this is due to higher transparency of reporting 
and/or under reporting in other states. Some of the larger differences in infection rates 
could be due to disease severity of patients with HAIs in ICU and non-ICU. Infection 
control measures need to target HAIs that are more prevalent and costly in the ICU.  





Nosocomial infection (NI), also known as Hospital-Acquired infection (HAI) or 
Healthcare Associated Infection (HCAI), is felt in every healthcare setting and its burden 
is significant. NI is one that occurs in a patient during the process of care in a hospital or 
other health care facility, which was not present or incubating at the time of admission. NI 
can affect patients in any type of setting where they receive care and can also appear after 
discharge. Furthermore, they include occupational infections among staff and represent the 
most frequent adverse event during care delivery, which no institution or country can claim 
to have solved the problem yet. According to the Center for Disease Control and 
Prevention, 90,000 people die each year from NIs in the United States and it costs a 
whopping $12 billion to deal with this health issue. Complex healthcare systems that share 
services and facilitate inter-institutional patient transfers provide an increased opportunity 
for rapid transmission of NIs (Centers for Disease Control and Prevention, 2014). As such, 
the magnitude of the problem in United States is significant and causes a high burden on 
morbidity and mortality. A majority of NIs include urinary tract infections, surgical site 
infections, pneumonia, and bloodstream infections.  
1.1 Nosocomial Infection – types and prevalence 
The various types of NIs and multiple forms of transmission routes make it very 
difficult to manage and control them. NIs are usually classified by the infection site such 
as surgical site infections (SSIs), central line associated bloodstream associated infections 
(CLABSIs), ventilator-associated pneumonias (VAPs), catheter-associated urinary tract 
infections (CAUTIs), and Clostridium Difficile-associated Infection (CDI) (Scott II, 2009). 




airborne. Irrespective of the level of control and stringent planning, NIs are present 
regardless of the level of resources available in a healthcare system due to prolonged and 
inappropriate use of invasive devices and antibiotics, high-risk and sophisticated 
procedures, immune-suppression and other severe underlying patient conditions, and 
insufficient/incorrect application of standard and isolation precautions.  
1.2 Problem Statement 
HAIs are a tremendous burden with an approximate 721,800 infections, 90,000 
deaths and $12B of additional costs to our healthcare system (Centers for Disease Control 
and Prevention, 2014). In an acute-care setting, ICUs are one of the most vulnerable areas 
for the development of HAI and represent one-third of the total in-patient costs (Pittoni & 
Scatto, 2009). Understanding the clinical and financial impact of HAIs helps to better 
manage its burden and reduce overall healthcare costs in an ICU (Jain, Miller, Belt, King 
& Berwick, 2006). Length of stay and mortality are important clinical indicators and total 
resource utilization in ICU as determined by billing is an important indicator of the cost.  
1.3 Study Objectives 
The objective of the study is to explore the clinical and financial impact of 
hospital-acquired infections (HAIs) in patients admitted to the ICU using statewide 
representative databases (HCUP) for the states of Washington, Florida, New Jersey and 
New York. 
1.4 Study Hypotheses 
This study aims to answer the following research questions: 




patients who have an ICU stay? 
Hypothesis 1: An association exists between HAIs and hospital LOS in patients 
who have had an ICU stay  
2. Is there an association between HAIs and hospital mortality in patients who 
have an ICU stay? 
Hypothesis 2: An association exists between HAIs and hospital mortality in 
patients who have had an ICU stay  
3. Is there an association between HAIs and hospital cost in patients who have an 
ICU stay? 
Hypothesis 3: An association exists between HAIs and hospital cost in patients who 
have had an ICU stay  
4. Does the association of HAIs to LOS, mortality and costs vary by type of HAI 
(as identified by diagnosis related codes) in patients who have ICU stay? 
Hypothesis 4: Association of HAI to LOS, mortality and costs vary by type of HAI 
in patients who have had an ICU stay  
5. Does the association of HAIs to LOS, mortality and cost vary by sex (male or 
female) in patients who have ICU stay? 
Hypothesis 5: Association of HAIs to LOS, mortality and cost vary by sex (male of 








2.1 Past Focus and Research  
In the United States (US), the National Nosocomial Infection Surveillance (NNIS) 
System was established in 1970 when selected hospitals routinely began reporting their 
nosocomial infection surveillance data for aggregation into a national database. Hospitals 
participating in the NNIS System provide general medical-surgical inpatient services to 
adults or children requiring acute care. Identity of the nearly 300 hospitals that 
participated in the initial NNIS System was kept confidential (Medscape, 2001). In a 
popular study on the Efficacy of Nosocomial Infection Control (SENIC) in 2007, an 
incidence of 4.5 NIs for every 100 hospital admissions was estimated to have an annual 
direct cost of $10 - $12 billion on the healthcare system (Medscape, 2001)..  Given its 
importance, the U.S. Department of Health and Human Services (HHS) identified the 
reduction of HAIs as an Agency Priority Goal for the department and launched the HAI 
Action Plan in 2008. The goal of this 5-year plan was to reduce the national rate of 
healthcare-associated infections by demonstrating significant, quantitative and 
measurable reductions in hospital acquired central line-associated bloodstream infections 
and catheter-associated urinary tract infections. While considerable progress has been 
made in reduction of HAIs, the projected annual costs of $12B on our healthcare system 
is still substantial and a huge burden (Performance.gov, 2013). Currently, NI associated 
infections are reported at most registered acute care setting through the National 
Healthcare Safety Network (NHSN). Other sources such as EIP (Emerging Infections 




Utilization Project) are used as well. On top of the financial impact, the burden of NIs on 
mortality and morbidity has been previously explored. In a study that was conducted in 
eight acute care hospitals belonging to the Duke Infection Control Outreach Network 
(DICON) from the states of North Carolina and Virginia, it was observed that nosocomial 
blood stream infections (NBSIs) have a positive correlation to increases in 90-day 
mortality, increased length of stay, and increased costs of care. The length of stay and 
mean costs attributable to NBSIs were 10 days and $43, 208 respectively (Kaye et al., 
2014).  
The prevalence of HAI and sustainability of infection control efforts, with the 
ultimate goal of HAI elimination has been studied. It has been observed that certain 
organizational cultures view HAIs simply as collateral damage, the inevitable price that 
needs to be paid for sophisticated and complex care across multiple different care giver 
segments. In other cases, the goal of average results compared to national averages was 
considered acceptable versus striving for high performance. Quite often, the prevalence 
of HAIs is often reported and interpreted in epidemiological terms and the true impact is 
masked. By leveraging clinical and financial indicators as measures of impact, we can 
better design and adopt suitable HAI control measures. It has been demonstrated that 
such HAI control measures are sustainable and can indeed reduce associated healthcare 
costs (Wilcox, Dave, 2000, Shannon, 2011). One of the main areas of concern for HAIs 
in an acute-care setting is the intensive care unit (ICU) as it tends to house more critical 
patients requiring closer monitoring, higher staff-to-patient ratios and assisted devices 
such as mechanical ventilators, telemetry devices, intravenous lines, tubes and others. 




attributable to ICU are steadily increasing and represent over 20% of the total in-patient 
costs (Pittoni, Scatto, 2009). It has also been estimated that approximately 10% of the 
patients admitted to ICUs develop HAIs. Thus, ICUs are increasingly becoming a key 
battleground in our fight against HAIs. To my knowledge, while previous studies have 
explored the impact of HAI in trauma and other acute care settings, the full nature of 
impact across the entire ICU setting using a publicly reported database such as the HCUP 
is still to be explored. 
Initial exploration of HAIs, its prevalence and burden, and economic variables were 
largely studied using qualitative methods. In one instance (Ella, Svenja, Karolin, Frank & 
Iris, 2013), a prospective study was conducted to establish a clear baseline for HAIs in a 
university hospital and its impact in intensive and critical care units. The impact of HAIs 
in multiple settings has been studied using a combination of systematic reviews and 
quantitative methods (prospective and retrospective). Interestingly, the effectiveness and 
impact of HAI control measures have been studied through extensive prospective studies 
(Forster et al., 2011, Jain, Miller, Belt, King & Berwick, 2006). It has been observed that 
since 2000, the quality of secondary data sources have largely improved, thus supporting 
a number of studies that have been conducted retrospectively leveraging this data (Necla, 
Esra, Semih, Saziye & Filiz, 2012, Glance, Stone, Mukamel & Dick, 2011, Kaye et al., 
2014). 
2.2 Past Policy Interventions to control HAI: Action Plan 2008 - 2015 
In recognition of health care-associated infections (HAIs) as an important public 
health and patient safety issue, the U.S. Department of Health and Human Services (HHS) 




Infections. Members of this committee included clinicians, scientists, and public health 
leaders representing a cross-section of health policy, regulatory and healthcare 
administrative organizations such as Administration for Community Living (ACL), 
Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and 
Prevention (CDC), Centers for Medicare & Medicaid Services (CMS), Food and Drug 
Administration (FDA), Health Resources and Services Administration (HRSA), 
Occupational Safety and Health Administration (OSHA), National Institutes of Health 
(NIH), Office of the National Coordinator for Health Information Technology (ONC), U.S. 
Department of Defense (DoD), U.S. Department of Veterans Affairs (VA) and others. 
The Steering Committee marshaled the extensive and diverse resources of the 
Department, formed public and private partnerships, initiated discussions that identified 
new approaches to HAI prevention and collaborations, and launched the HAI Action Plan. 
The HAI Action Plan provided a road map for preventing HAIs in acute care hospitals, 
ambulatory surgical centers, end-stage renal disease facilities, and long-term care facilities. 
The HAI Action Plan also included a chapter on increasing influenza coverage of health 
care personnel and was organized into three phases; 1) Phase One - Acute Care Hospitals, 
2) Phase Two - Outpatient Settings and Influenza Vaccination of Health Care Personnel, 
and 3) Phase Three - Long-Term Care Facilities. Key stakeholders across each of these 





FIGURE 1: STAKEHOLDERS AND ORGANIZATION STRUCTURE – HAI ACTION PLAN 
The HAI Action Plan also assigned specific responsibilities across each phase to a specific 
organization. For instance, focus on prevention and implementation in Phase I was 
assigned to Centers for Diseases Control and Prevention whereas the financial 
reimbursement and incentives was assigned to Centers for Medicare and Medicaid Services 
(CMS).  This responsibility map across the HAI Action Plan is outlined in Figure 2. The 
HAI Action plan decided to take a phased approach and concentrate its activities and the 
content on six high-priority areas within an acute care setting. In addition, the Steering 
Committee included in the Action Plan five-year goals for specific measures of 
improvement tied to the six HAI prevention priority areas. This allowed the resources to 




expertise and experience both within and outside HHS in HAI prevention in the acute care 
setting. Table 1 represented below outlines these priority areas and five-year goals. 
 
TABLE 1: ACTION PLAN 2008 – 2013 PRIORITY AREAS AND FIVE-YEAR GOALS 
 
FIGURE 2: HAI ACTION PLAN RESPONSIBILITY MAP 
The HAI Action plan decided to take a phased approach and concentrate its 




the Steering Committee included in the Action Plan five-year goals for specific measures 
of improvement tied to the six HAI prevention priority areas. This allowed the resources 
to concentrate and be dedicated to this effort and also take advantage of the substantial 
expertise and experience both within and outside HHS in HAI prevention in the acute care 
setting. Table-2 outlines these priority areas and five-year goals.  
 
TABLE 2: HAI ACTION PLAN PRIORITY AREAS AND RESULTS (THROUGH 2012) 
In order to solidify participation from hospitals, end-stage renal and long-term care 
facilities, the Incentives and Oversight team provided recommendations to expand the 
scope of regulatory oversight specifically around Conditions of Participation (CoPs) and 
Conditions for Coverage (CfCs), accreditation, survey and certification. It was 
recommended that hospitals ensure that their hospital infection control follows currently 
recognized national standards of practice and make infection control program an integral 
part of the hospital’s quality assessment and performance improvement program. 
The results of the HAI Action Plan have been reviewed periodically and steady 
progress has been reported since the launch of the program (U.S. Department of HHS, 
2014). Some of the key results reported through October 2012 include: 




infections, health care-associated invasive methicillin-resistant Staphylococcus 
aureus (MRSA) infections, and surgical site infections, constituting timely progress 
toward the 5-year targets; 
 Improvement in compliance with all five Surgical Care Improvement Project process 
measures to reduce the risk of surgical site infections; 
 Leveling of hospitalizations with Clostridium difficile infection, but not a marked 
decrease. More work is needed to reduce the rate to meet the 2013 goal 
Table 2 (column “on track to meet 2013 targets”) outlines the summary of progress towards 
the national targets for elimination of Health Care-Associated Infections. Full results of the 
HAI Action Plan are awaited to conclude the results across each of the priority areas and 
for the full five-year duration. This HAI Action Plan concluded on December 31, 2013 and 
its conclusive results across the 5-year duration are expected to be published by end of 
2014. A new HAI Action Plan 2020 has been launched with a revised set of targets (U.S. 
Department of HHS, 2014). 
2.3 Future Policy Interventions for HAI Control: Action Plan 2020 
For 2015 and beyond, HAI control continues to be a prime focus at the national 
level. A number of key policies and programs have been instituted to keep up the pace of 
progress and address some of the shortcomings of the previous plan.  The Office of Disease 
Prevention  and Health Promotion (ODPHP) provides national leadership in disease 
prevention and health promotion by creating national goals and objectives, coordinating 
HHS preventable health services and supporting public/private health programs. ODPHP 
is part of the U.S. Department of Health and Human Services (HHS) under the Office of 




overseeing the institution of the HAI Action Plan 2020 policy and various aspects of its 
implementation (ODPHP, 2015). 
2.3.1 Current state of HAI Action Plan 2020 
Since the conclusion of the previous HAI Action Plan in 2013, the HAI Action Plan 2020 
has been in the formulation stage. Various agencies that were associated with the previous 
plan have been asked to provide input. In addition, the Federal Register has issued a citation 
requesting public comments to the HAI Action Plan 2020, specifically focusing on 
measures for acute care hospitals. This citation was issued on February 25, 2014 and the 
period to receive comments concluded on March 27, 2014 (HAI 2020 Citation, 2014). In 
parallel, with the expiration of the previous HAI Action Plan, a Steering Committee has 
been formulated that has identified new five-year goals to measure national progress in 
HAI reduction. The new goals will continue to use data from the Centers for Disease 
Control and Prevention's National Healthcare Safety Network (NHSN) as well as data from 
the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Program 
(HCUP). The new targets will set baseline rates using data from 2015 and establish goals 
to be achieved by December 2020. The proposed targets take into account HAI reductions 
to date and will reflect progress that takes place between 2013 and 2015. Selecting a single 
baseline year for measuring progress toward the targeted goals in acute care hospitals—
and using that same baseline year for purposes of quality measure reporting to the Centers 
for Medicare and Medicaid Services (CMS) and public reporting on CMS's Hospital 
Compare Web site—is expected to improve consistency in federal HAI measurement and 
reporting efforts. The proposed targets are intended to align with the HAI targets in Healthy 




2.3.2 Interrelationship and timeline 
The HAI Action Plan 2020 is anticipated to draw inputs from several current policies and 
programs instituted at the national level. These programs have been primarily championed 
by ODPHP and are linked to public health and patient safety. Partnership for Patients aims 
to reduce preventable hospital acquired conditions by 40% and hospital readmissions by 
20% compared to baseline of 2010 (PartnershipForPatients.cms.gov, 2015). Healthy 
People 2020 aims to identify nationwide health improvement priorities, increase public 
awareness and understanding of determinants of health, disease, and disability, provide 
measurable objectives and engage multiple sectors (HealthyPeople.gov, 2015). CMS 
Healthcare-acquired Conditions (HACs) is a set of conditions that apply to reimbursement 
and penalties based on effectiveness of HAI control efforts at the unit level (for instance, 
acute care hospitals). On July 31, 2008, in the Inpatient Prospective Payment System 
(IPPS) Fiscal Year (FY) 2009 Final Rule, CMS included 10 categories of conditions that 
were selected for the Hospital Acquired Conditions (HACs) payment provision. Payment 
implications began October 1, 2008, for these HACs (HACs - CMS.gov, 2014). The 
interrelationship of HAI Action Plan 2020 with all of these other policies and programs are 





FIGURE 3: HAI ACTION PLAN 2020 INTERRELATIONSHIP AND TIMELINE 
2.3.3 HAI Action Plan 2020 Targets 
The U.S. HHS has released proposed targets and metrics for the National Action Plan to 
Prevent Healthcare-Associated Infections, as virtually all of the previous targets and 
metrics expired December 2013. A national stakeholder meeting was held in September 
2013 and helped shape the proposed targets along with a federal steering committee of HAI 
prevention experts from federal agencies. The proposed targets would set 2015 as the new 
baseline, with the exception of invasive MRSA, which was included in the federal 
government’s Healthy People 2020 goals and has an existing 2007-2008 baseline, which 
has not expired. Table 3 outlines the proposed new targets for 2020, alongside the most 






TABLE 3: HAI ACTION PLAN 2020 METRICS 
As noted above, the proposed targets for 2020 aim for 30%-75% reduction across various 
categories of HAIs. It remains to be seen how and what extent of progress can be achieved 
in the hard-to-control HAIs such as CAUTI and MRSA in which very minor progress has 
been made since 2010. 
2.4 Prevalence of HAI and its impact 
The prevalence of HAIs in a healthcare setting is significant and its burden is real. 
Several studies have examined this problem and the importance of understanding key risk 
factors for HAIs and infection control efforts (Wilcox & Dave, 2000a, Ella, Svenja, 
Karolin, Frank & Iris, 2013). A strong correlation between patient safety and elimination 
of HAIs has been established.  The business case for reduction of HAIs is a compelling 
one, offering substantial economic incentives for achieving the necessary goal of 
improved patient outcomes and safety (Hwang & Herndon, 2007). In a study that was 




only are HAIs morbid and costly, but they could be eliminated through infection control 
efforts that include standardization of work and optimization (Shannon, 2011).   
The path to elimination of HAIs and reduction of its impact on our healthcare system 
can be achieved by assessing its prevalence in many different settings, including 
intensive and critical care units. At the national leadership convention held September 8-
9, 2008 in Washington DC, leaders across a cross-section of various types of healthcare 
organization all felt every hospital leader should reevaluate the strategy, structure, and 
function of their infection control and prevention services to reduce overall costs and 
improve patient safety (Denham et al., 2009). Intensive care units (ICUs) consume a 
significant amount of hospital resources under operating conditions that are susceptible to 
higher incidence of sepsis and HAIs. Infection control efforts in these units may help to 
reduce overall ICU costs and help manage healthcare resources more effectively in a 
hospital setting (Pittoni & Scatto, 2009). In a study on to clostridium difficile infection 
(CDI), it was discovered that 95% of the additional hospital costs were a result of its 
direct impact on length of stay (LOS) (Wilcox & Dave, 2000b). Thus, understanding the 
clinical impact of HAIs in an ICU setting will help drive better infection control efforts. 
2.5 Impact of HAI Control Efforts 
Many different analytical models have been analyzed for estimating costs and impact 
of HAIs. A systematic review highlighted that researchers need to be more discerning in 
the selection of methodologies for their analysis, and comparative analysis may be 
needed to identify more accurate estimation methods. This review also concluded that 
shifts in methodologies for impact analysis is leaning more towards regression analysis 




published post 2000 (Fukuda, Lee & Imanaka, 2011). For instance, one particular study 
compared the impact of HAIs on medical costs, mortality, LOS and health outcomes 
between community hospitals and medical centers (Sheng et al., 2005). Interestingly, 
another study in Belgium sought to assess the impact of HAIs on LOS and healthcare 
costs using national surveillance data in Belgium. The results of this study concluded that 
bloodstream HAIs increased length of stay by ten days and the time to infection played a 
crucial role in infection control (Vrijens et al., 2010). In 2014, a related study was 
conducted to assess the impact of bloodstream HAIs on older adults and the results 
demonstrated increases in LOS, 90-day mortality and cost of care (Kaye et al., 2014). A 
different study was conducted to ascertain the impact of HAIs on trauma patients using a 
nationally representative database. This study also leveraged LOS and mortality as 
clinical measures and billing as the financial measure of impact. After controlling for 
patient demographics, mechanism of injury, injury type, injury severity, and 
comorbidities, this study found that mortality, cost, and LOS were significantly higher in 
patients with HAIs compared with patients without HAIs (Glance, Stone, Mukamel & 
Dick, 2011). However, no literature was found related to studies conducted to ascertain 
the impact of HAIs within an ICU in the United States using a nationally or state-wide 
representative database such as HCUP. Also, many of the past studies have focused on 
assessing the broad impact of HAIs to healthcare or to a hospital/health system. Given 
that ICU consume significant amount of healthcare resources within an acute care setting, 
understanding the clinical and financial impact of HAIs in this setting may help hospital 
leaders and Infection Prevention teams to better design infection control and quality 




within the ICU have demonstrated positive results in the reduction of HAIs, LOS, 
mortality and overall cost (Jain, Miller, Belt, King & Berwick, 2006, Forster et al., 2000). 
2.6 Literature Search 
To be able to synthesize current evidence, identify key perspectives, and incorporate 
recommendations into this study, a wide cross-section of literature was examined by 
performing a multi-field search of the Ovid/MEDLINE library database for articles 
published between 1996 to July week 2, 2015. All fields in Ovid/MEDLINE were 
leveraged for the search and Boolean operators were adequately used to derive a 
comprehensive search. The search terms were divided into the following categories to 
derive focused search results; 1) Hospital Acquired Infections, which included “Hospital 
Acquired Infections”, “Nosocomial Infections”, 2) Impact of Hospital Acquired 
Infections, which included “Impact of Hospital Acquired Infections”, and “Impact of 
Nosocomial Infections”, and 3) Intensive Care Units, which included “Intensive Care 
Unit” and “ICU”.  
2.4.1 Inclusion and exclusion criteria 
Literature articles were included if they matched the topic of HAIs, had any 
viewpoint on impact or burden to healthcare and/or had perspectives on how HAIs would 
impact patients in ICU. Full text evaluation of each result was attempted and all 
irrelevant results to the topic chosen were removed. 
2.4.2 Search Results 
The cumulative search results returned back about 410 records. Figure 4 
summarizes the process undertaken to identify all relevant articles. After removal of 




articles for the literature review.  
 
FIGURE 4: FLOW DIAGRAM OF RESULTS FOR INCLUSION 
Each article in the final set of results was reviewed for its objective, design 
method, data collection, analysis, results and conclusion. Based on a full review of the 
text and analysis content, these articles were categorized into the following areas for 
easier analysis and cross-correlation: 1) Prevalence of HAI, to understand its 
characteristics and burden, 2) Evaluation of HAI Impact, to understand research 
conducted to understand its impact, and 3) Impact of HAI control efforts, to explore 





3.1 Study Design 
This Study was a multi-state hospital billing data retrospective cohort study. 
Secondary data sources was leveraged for analysis with patients identified with and 
without a diagnosis for a HAI on the discharge record based on ICD-9 diagnosis codes. 
The outcome variables of interest were in-hospital mortality, hospital length of stay 
(LOS), and hospital cost. Adjusted odds ratio from a multivariable logistic regression 
analysis was used to assess the effect size of the relationship between HAI and mortality. 
Multiple generalized linear models were used to assess the relationship between HAI on 
hospital cost and LOS. Backward stepwise selection methods and clinical judgment were 
applied for inclusion/exclusion of independent variables. Analysis were conducted using 
SAS statistical computing software and Microsoft Excel. All tests were two-sided and 
statistical significance was assessed at the α=0.05 level. A high-level flow of this design 
is outlined below in Figure 5. 
 





The association between HAI and outcomes were examined.  
3.2.1 Study Objectives 
The objective of the study was to explore the clinical and financial impact of 
hospital-acquired infections (HAIs) in patients admitted to the ICU using statewide 
representative databases (HCUP) for the states of Washington, Florida, New Jersey and 
New York. 
3.2.2 Study Hypotheses 
This study aimed to answer the following research questions: 
1. Is there an association between HAIs and hospital Length of Stay (LOS) in 
patients who have an ICU stay? 
Hypothesis 1: An association exists between HAIs and hospital LOS in patients 
who have had an ICU stay  
2. Is there an association between HAIs and hospital mortality in patients who 
have an ICU stay? 
Hypothesis 2: An association exists between HAIs and hospital mortality in 
patients who have had an ICU stay  
3. Is there an association between HAIs and hospital cost in patients who have an 
ICU stay? 
Hypothesis 3: An association exists between HAIs and hospital cost in patients who 
have had an ICU stay  




(as identified by diagnosis related codes) in patients who have ICU stay? 
Hypothesis 4: Association of HAI to LOS, mortality and costs vary by type of HAI 
in patients who have had an ICU stay  
5. Does the association of HAIs to LOS, mortality and cost vary by sex (male or 
female) in patients who have ICU stay? 
Hypothesis 5: Association of HAIs to LOS, mortality and cost vary by sex (male of 
female) in patients who have had an ICU stay  
3.3 Data Sources 
For this study, the Healthcare Cost and Utilization Project (HCUP) Statewide Inpatient 
Samples from 2012 for California (CA), New York (NY), New Jersey (NJ) and Florida 
(FL) were utilized. The inclusion of patients is based on the U_ICU and U_CCU flags of 
the database. Exclusion of patients is based on ICD-9-CM codes  from the hospital 
discharge bills based on, conditions such as bone-marrow transplants, unspecified 
injuries, organ transplants and cancer, and transferred status (transferred-in or transferred-
out), which are shown in Table 4. 
 Exclusion Criteria Codes 
Bone-marrow transplants ICD-9-CM: 41.0 – 41.09, V42.81 
Organ transplants ICD-9-CM: V42.0 – V42.9 
Cancer ICD-9-CM: 188.x, 170.x, 191.x, 174.x, 180.x, 153.x, 
193, 194.x, 150.x, 152.x, 176.x, 189.x, 204.xx – 208.9x, 
140.x, 155.x, 162.x, 200.xx – 203.02, 183.x, 157.x, 
158.x, 185, 172.x, 151.x, 186.x, 141.x, 182.x, 197.x, 




Chemotherapy, Immunotherapy ICD-9-CM: V58.11, V58.12 
Drugs, Medicinal and Biological 
Substances causing Adverse 
Events in Therapeutic Use 
ICD-9-CM: E930 - E949 
Transfer status (transferred in 
and transferred out) 
TRAN_IN = 1 
 
TABLE 4: EXCLUSION CRITERIA AND ASSOCIATED CODES   
3.4 Measurement of Variables 
The outcome variables are length of stay, mortality and cost, which were 
determined by the fields LOS, DIED and TOTCHG. LOS is a continuous variable with 
the value represented in days. DIED indicates died during hospitalization and is coded 
from the discharge disposition of the patient (value of 1 indicates died during 
hospitalization). TOTCHG is a continuous variable with value representing rounded 
charges in USD. Bills with missing charges will be excluded from the analysis (“.” for 
missing, “.A” for invalid, “.B” for unavailable from source, and “.C” for inconsistent). 
Final hospital costs will be calculated by multiplying TOTCHG by the hospital average 
cost to charge ratios. Patients that do not have HAIs will be the comparison group for all 
analyses. Patients with HAIs are those with the ICD-9-CM diagnosis codes (DXn, n >=1 
and DXPOAn = “N”) as listed in Table 5 with HAI = “Y”. This categorization of HAIs is 





Classification  Criteria HAI 
(Y/N) 
ICD-9-CM Discharge Diagnosis 
Codes 
(+ Code must be concurrent with 






any Sepsis in 
coding 
Y 038-038.9, 112.5, 112.81, 785.52, 






infection due to 
venous catheter 





































Y 730.0-730.09, 711-711.09, 038.11, 
041.11, 482.41, V09.0, V09.8, 008.41, 
038.1, 790.7, 996.62, 421.0, 996.61, 










TABLE 5: ICD-9-CM DISCHARGE CODES FOR HAIS  
The above classification of HAIs is also consistent with previous studies because of their 
careful and clear use (Glance, Stone, Mukamel & Dick, 2011).   
3.5 Data Collection 
Secondary data sources were used for the study with no primary data collection 
effort. The HCUP State Inpatient Databases (SID) year 2012 was available and used as 
the main source. Agency for Healthcare Research and Quality (AHRQ) co-morbidity 
measures were used as the reference to exclude patients with certain conditions. This 
study was considered “non-human research” by the MUSC IRB.   
3.6 Data Analysis 
Descriptive statistics were used to compare the characteristics of the HAI 
population and ICU patients with no diagnosis of HAI. We then used logistic regression 




known HAI. Finally, we used multiple generalized linear regression to compare the cost 
and LOS between the 2 groups. Using multiple regression, the relationship among 
variables may be determined, or as an inferential method, to test the study hypothesis 
about population parameters (Leiyu, 2008). Additional subgroup were done to assess the 
relationship between the independent variables and different types of HAI. 
Independent variables that may be used to control for potential confounding 
differences between HAI and no-HAI groups were: patient characteristics and 
comorbidities. Details for each are highlighted in the below Table 6. 
Independent Variables Details 
Patient Characteristics Age, Race and Sex (Male/Female) 
Comorbidities Charlson (Comorbidity) Index  
 
TABLE 6: INDEPENDENT VARIABLES TO CONTROL FOR CONFOUNDING FACTORS 
Covariates not found to significantly contribute to each model were removed one 
at a time, and the models will then be refit to the data using standard model fitting 
methods. The effect of sepsis and other specific HAI on mortality were assessed using 
adjusted odds ratio (AOR). Effect of HAI on hospital costs and LOS were assessed by 
estimating the adjusted hospital cost and LOS for patients with HAI and patients without 
HAI. 
3.7 Data Management and Quality Assurance (QA) 
The HCUP SID dataset is safeguarded to protect privacy. The principal investigator 
will successfully complete the HCUP Data Use Certification and execute the Data Use 




certification as required by the AHRQ. The internal procedures used to protect the data in 
this study will be compliant with the Data Use Agreement such as secured storage, 
protected data access, and privacy protection of hospital or patient identifiable 
information.  
HCUP data was validated using a third-party contracting firm, as part of the AHRQ 
quality assurance process. To assure accurate Statistical Analysis System (SAS) coding, 
AHRQ employed dual analysts to independently write SAS code for any changes made in 
calculating readmission measures, including data preparation, sample selection, 
hierarchical modeling, and readmission calculation. Once the parallel programming 
process was complete, the analysts crosschecked code by analyzing the dataset in 
parallel, checking for output consistency and reconciling any discrepancies. In a second 
QA phase, an HCUP data analyst reviewed the integrity and readability of the SAS code, 
making recommendations for coding or program documentation improvements to the 





Patient records from four HCUP Statewide Inpatient Databases (SID) for NJ, FL, NY 
and WA were examined using a Statistical Programming Tool (SAS). The frequency 
distribution of HAIs in these datasets were calculated through the appropriate statistical 
test based on the distribution (categorical or continuous).  The results were compiled into 
specific areas to drive each of the hypothesis stated earlier in Chapter 3.   
4.1 Overview 
A total of 584,749 discharge records pertaining to their ICU visit were examined from the 
HCUP Statewide Inpatient Databases (SID) for NJ (99,713), FL (314,506), NY (124,817) 
and WA (45,713). A total of 57,616 infections of some form was recorded in patients 
after their ICU stay with LOS >= 3 days across the population set.  For patients admitted 
to the ICU in these states, sepsis represented the highest form of HAI at 27,107 infections 
(35%) followed by Urinary Tract Infection (generic) at 22,507 (29%), Staph Infections at 
11,317 (15%), CDIFF Infections at 6,973 (9%), Pneumonia at 5,107 (7%), Bacteremia at 
2696 (3%), CLABSI at 1,424 (2%) and CAUTI at 680 (1%). WA recorded the highest 
level of infections in ICU at 13,413 out of 45,713 (29%) followed by NY at 14,273 out of 





FIGURE 6: DISTRIBUTION OF HAIS BY STATE AND TYPE OF INFECTION    
If the record sets are filtered to only include those patients that have the specific ICD-
9-CM codes associated for six HAIs (Sepsis, CAUTI, CDIFF, Staph, Pneumonia, and 
CLABSI), the total number of infections across NJ, NY, FL and WA dropped to 41,729 
out of 584,749. WA still recorded the highest infections within the ICU at 9,848 out of 
45,713 (21%) followed by NY at 10,815 out of 124,817 (9%), NJ at 5,210 out of 99,713 
(5%) and FL at 15,856 out of 314,506 (5%). Figure 6 outlines these statewide distribution 
of infections and the corresponding infection rates. In this graph, Total represents the 
total number of patients admitted to the ICU. All Infection comprises of the cumulative 
set of infections that include Sepsis, Pneumonia, Bacteremia (generic), CLABSI, UTI 
(generic), CAUTI, Staph and CDIFF. HAI includes the six categories of Sepsis, 
Pneumonia, CLABSI, CAUTI, Staph and CDIFF. Infection% is the infection rate for the 






FIGURE 7: COMPARISON OF INCIDENCE OF HAIS AND FOLD INCREASE BY STATE  
4.2 Patient Characteristics  
The characteristics of patients in ICU were compared across three categories: patients 
with no HAI, patients with HAI, and patients with infections (UTI or Bacteremia) that 
have not been classified as HAI. The p-value has been calculated considering the 
candidate population (patients with HAI) versus the control group (patients with no HAI). 
Characteristics such as age, race, admission type, sex (male or female), comorbidity, 
length of stay (LOS), total cost (leveraging TOTCHG and hospital cost to charge ratios) 
and mortality rate (leveraging DIED) were examined. Each of these characteristics have 
been operationalized as State, Age, Race, Admission Type, Comorbidity, Clinical, and 
Financial indicators. Missing values are indicated wherever applicable. 
 





































































































































Comorbidity Charlson Score 1.581 1.555 1.607 <0.0001 
Clinical LOS (in days) 15.590 8.871 22.31 <0.0001 





Financial Total Cost 
(USD) 
$43,682.37 $21,437.94 $65,926.79 <0.0001 
 
*p-values were calculated using independent sample t-tests for continuous measures 
and Chi-square tests for categorical measures 
 
TABLE 7: PATIENT CHARACTERISTICS ACROSS CATEGORIES 
 
4.3 Hypothesis 1: Impact of HAI on LOS  
Out of a total of 584,749 observations, 584,571 were utilized after factoring in 
missing values in 178 records. The LOS was analyzed using negative binomial 
distribution with logarithmic link function and PROC GENMOD in the SAS statistical 
software.  Dispersion parameter was estimated by maximum likelihood and the 
coefficient was -0.9136 with the Wald 95% confidence limits tight between -0.9196 and -
0.9076 and statistically significant p-value of < 0.0001. Per least squares means, it was 
determined the average LOS for patients with HAI in ICU was 22.9 days versus those 
patients in ICU without HAI at 9.2 days (Table 8). Thus, LOS is significantly higher 







Estimate Standard Error LOS 
No 2.2196 0.001202 9.2041 
Yes 3.1333 0.003021 22.9487 
 
TABLE 8: ADJUSTED AVERAGE LOS FOR PATIENTS IN ICU  
 
4.4  Hypothesis 2: Impact of HAI on Mortality  
Mortality (DIED) was analyzed using the binary logistic regression model. Out of a 
total of 584,749 observations, 584,569 were utilized after factoring in missing values in 
180 records. Analysis of maximum likelihood was conducted and the coefficient was 
1.9670 with a p-value of < 0.0001. Various factors such as AGE, RACE, ATYPE and 
SEX were analyzed and all were significantly associated with HAI in ICU patients with 
p-value of < 0.0001; however, it is important to note the study’s statistical power to 
detect small differences. Thus, we examined the association of each factor with looking 
at odds ratio and confidence intervals.  






Presence of ANY HAI 7.149 6.951 7.352 
AGE 1.026 1.025 1.027 
FEMALE 0.826 0.806 0.846 
Comorbidity (using Charlson Score) 1.008 1.000 1.016 
RACE (Black vs. White) 1.203 1.161 1.247 
RACE (Hispanic vs White) 1.092 1.050 1.136 





TABLE 9: ADJUSTED ODDS OF MORTALITY 
 
As can be observed in Table 9, HAI in patients within ICU has a significant impact on 
mortality. Patients with any HAI have 7.15 times higher odds of death compared to those 
that do not have HAI in ICU, while controlling for age, sex, comorbidity, and race. The 
95% Wald confidence limits are very precise between values of 6.951 and 7.352. AGE, 
male gender, greater comorbidity and minority race are all significant indicators of 
increased odds of mortality.  
4.5 Hypothesis 3: Impact of HAI on Hospital Costs 
Out of a total of 584,749 observations, 538,864 were utilized after factoring in 
missing values in 45,885 records. The cost outcome was analyzed using a generalized 
linear model using a Gamma distribution with logarithmic link function (PROC 
GENMOD in the SAS statistical software).  The Scale parameter was estimated by 
maximum likelihood and the coefficient was -1.1063 with the Wald 95% confidence 
limits tight between -1.1148 and -1.0979 and statistically significant p-value of < 0.0001. 
Adjusted estimates of hospital costs for patients with HAI in ICU was 3.02 times more 
expensive than for patients without HAI in ICU ($66,503 versus $22,659 respectively) as 
highlighted in Table 10. Thus, HAI has a significant impact on hospital costs on patients 
with HAI in ICU. 
With HAI 
Log 
Estimate Standard Error 
Adjusted Total 
Cost 
No 10.0283 0.001448 $22,659 
Yes 11.1346 0.004263 $68,503 
 




4.6  Hypothesis 4: LOS, Mortality and Cost by HAI Type 
In order to compare the LOS, Mortality and Cost by each individual HAI type, the 
specific statistical models for each type of dependent variable (GENMOD, Logistic and 
GENMOD respectively) were computed for each type of HAI: Sepsis, CLABSI, CAUTI, 
Pneumonia, Staph, and CDIFF. The results from these eighteen models are computed in 
the below summary tables for each dependent variable. 
4.6.1 LOS by HAI Type 
LOS dependent variables for each type HAI type were analyzed using negative 
binomial distribution with logarithmic link function and PROC GENMOD in the SAS 
statistical software.  Dispersion parameters were estimated by maximum likelihood and 
least squares means was used to determine the corresponding exponents. These results 
are summarized in Table 11.   
As can be observed from Table 11, every type of HAI significantly impacts LOS in 
patients within ICU. However, patients with CLABSI HAI in ICU have 4 times the 
estimated average LOS (40.76 days versus 10.16 days, p-value<0.0001) than patients 
without HAI. ICU patients with Sepsis had increased average LOS when compared to 
ICU patients without sepsis (22.83 days versus 9.58 days respectively, p-value <0.0001), 





Least Squares Means (All HAI Types)  
Total = 584, 749, n = 584,571, missing = 178 






Sepsis No 2.2598 0.001226 9.5816 
Yes 3.1281 0.003838 22.8306 
CLABSI No 2.3190 0.001247 10.1660 
Yes 3.7078 0.01670 40.7630 
CAUTI No 10.1488 0.001520 8.1660 
Yes 11.1348 0.03640 34.3456 
Pneumonia No 2.3088 0.001240 10.0623 
Yes 3.4236 0.008860 30.6787 
Staph No 2.2925 0.001231 9.9001 
Yes 3.3056 0.005936 27.2637 
CDIFF No 2.3081 0.001245 10.0554 
Yes 3.2307 0.007684 25.2961 
 
 
TABLE 11: ADJUSTED LOS FOR PATIENTS IN ICU BY HAI TYPE 
 
4.6.2 Mortality by HAI Type 
Mortality (DIED) for all HAI types were analyzed using the binary logistic regression 




covariates such as AGE, RACE, ATYPE and SEX were included in the multivariable 
models and all were significantly associated with HAI in ICU patients with p-value of < 
0.0001. Adjusted odds and 95% confidence intervals for the odds of mortality in the HAI 
type subgroup when compared to not having that HAI type are shown in Table 12. 
 Odds of Mortality 
HAI Type Odds Ratio 
OR 95%   
Confidence Limits 
Sepsis 9.671 9.380 9.972 
CLABSI 4.180 3.617 4.832 
CAUTI 1.303 0.962 1.766 
Pneumonia 5.045 4.696 5.419 
Staph 3.122 2.946 3.308 
CDIFF 3.422 3.198 3.661 
 
TABLE 12: ADJUSTED ODDS OF MORTALITY FOR EACH HAI TYPE 
 
All HAIs have an association on mortality for patients in ICU. Patients in ICU with 
Sepsis had the highest odds of mortality at 9.671 times the mortality of patients without 
Sepsis in ICU. Similarly, patients in ICU with CAUTI had the lowest odds of mortality at 
1.303 times the mortality of patients without CAUTI in ICU, and this was not statistically 
significant (p-value =0.08). All other HAI types had higher odds of mortality ranging 
from 3.1 to 5.0 higher odds in the HAI group when compared to patients with no 
indication of that HAI. Thus, in almost all types of HAI, there is a significant increase in 
odds of mortality, however this increase varies by individual type of HAI.  
4.6.3 Cost by HAI Type 




distribution with logarithmic link function and PROC GENMOD in the SAS statistical 
software.   
 
Adjusted Average Cost (All HAI Types)  
Total = 584, 749, n = 584,571, missing = 178 
HAI Type With HAI Log 
Estimate 
Standard 
Error Adjusted Cost 
Sepsis No 10.0707 0.001473 $23,641 
Yes 11.1861 0.005503 $72,122 
CLABSI No 10.1417 0.001514 $25,380 
Yes 11.5449 0.02193 $103,254 
CAUTI No 10.1488 0.001520 $25,560 
Yes 11.1348 0.03640 $68,517 
Pneumonia No 10.1280 0.001502 $25,033 
Yes 11.4755 0.01245 $96,326 
Staph No 10.1115 0.001493 $24,625 
Yes 11.2829 0.008258 $79,452 
CDIFF No 10.1305 0.001511 $25,097 
Yes 11.1092 0.01035 $66,782 
 
 





Dispersion parameters were estimated by maximum likelihood and least squares 
means was used to determine the corresponding exponents. These results are summarized 
in Table 13.  As can be observed from Table 13, every single type of HAI increases total 
cost in patients within ICU. However, patients with CLABSI HAI in ICU have 4.06 times 
the total cost ($103,254 versus $25,380) than patients without HAI and the highest 
association of increased total cost. Patients with CDIFF in ICU recorded the lowest 
association of 2.6609 times than those patients without HAI in the ICU followed closely 
by CAUTI at an observed association of 2.6806 times than those patients without HAI in 
the ICU. 
4.7 Hypothesis 5: LOS, Mortality and Cost by Sex (Male/Female) 
In order to compare the LOS, Mortality and Cost by Sex, the specific statistical 
models for each type of dependent variable (GENMOD, Logistic and GENMOD 
respectively) were computed for each of the two values of Sex, i.e., Female = 1 and 
Female (Male) = 0. The results from these six models are computed in the below 
summary tables for each dependent variable 
4.7.1 LOS by Sex  
As can be observed from Table 14, both Male and Female patients with HAI in the 
ICU have increased adjusted LOS compared to the same gender group without HAI 
(p<0.0001). However, Males with and without HAI in ICU have increased LOS (9.45 and 





Least Squares Means (Female = 1, 0)  
Female = 1: Total = 294,159, n =294,069, missing = 90 
Female = 0: Total = 290,586, n =290,502, missing = 84 




Male No 2.2465 0.001726 9.4544 
Yes 3.1724 0.004235 23.8640 
Female No 2.1929 0.001676 8.9613 
Yes 3.0924 0.004315 22.0303 
 
TABLE 14: ESTIMATED LOS BY HAI AND SEX 
 
4.7.2 Mortality by Sex  
Mortality (DIED) for Male and Female patients were analyzed using the binary 
logistic regression models. For Male and Female, various factors such as AGE, RACE, 
ATYPE and SEX were analyzed and all were significantly associated with HAI in ICU 











Male 6.869 6.611 7.136 
Female 7.494 7.192 7.809 
 
TABLE 15: ODDS OF MORTALITY IN THE HAI GROUP WHEN 
COMPARED TO THE NO HAI GROUP BY SEX  
 
As can be observed in Table 15, both Male and Female have a much higher odds of 
mortality if they have an HAI when compared to no HAI. However, Female patients with 
HAI in ICU have a higher odds of mortality at 7.494 times the mortality of patients 
without HAIs in ICU. Male patients with HAI in ICU had a lower association with 
mortality at 6.869 times the mortality of patients without HAIs in ICU.  
4.7.3 Cost by Sex  
As can be observed from Table 16, both Male and Female patients with HAI have 
much higher total adjusted hospital costs. Female patients with HAI in ICU have 3.05 
times the total cost ($65,440 versus $21,481) than female patients without HAI and 
higher association of increased total cost compared to Male patients. Male patients with 
HAI in ICU recorded lower association of total cost at 3 times more than those male 




Adjusted Hospital Costs 
 




Male No 10.0827 0.002068 $23,925 
Yes 11.1821 0.005917 $71,835 
Female No 9.9749 0.002033 $21,481 
Yes 11.0889 0.006156 $65,440 
 






Infections in ICU adversely impact key clinical and financial indicators of patients 
such as LOS, mortality and cost. Results of this study have shown that all HAI types are 
significantly associated with LOS, mortality and total cost. Based on the HCUP SID, 
certain states such as WA record significantly higher infection rates than other states as 
represented by its 29% overall infection rate and 22% HAI infection rate. In contrast, 
other states such as FL, NY and NJ record  infection rates of 11%, 7% and 7% 
respectively and HAI infection rates of 9%, 5% and 5% respectively. Such significant 
differences in infection rates may need to be explored further and could be due to higher 















































TABLE 17: UTI AND BACTEREMIA BY STATE 
As can be observed from Table 17, other infections such as UTI and Bacteremia are also 




total HAI infections. Based on the data, it is unclear if these UTI and Bacteremia 
infections are caused due to HAI or general infections. The reason for incorrect 
categorization may be either due to incorrect coding or possible motivation for coding not 
to contribute towards HAI.  To determine the true causality, it needs to be further 
explored if these UTI infections are induced through catheter usage and thus should to be 
classified under CAUTI. Doing so would elevate the already higher HAI infection rates 
for WA, NY and other states. Similarly, while the number of observed Bacteremia 
infections are low, it needs to be explored if these infections are induced through usage of 
central line and thus could potentially be classified as CLABSI. Analysis of the diagnosis 
code in HCUP records for UTI and Bacteremia codes (ICD-9) do not yield conclusive 
results in terms of HAI determination due to missing values or invalid coding.         
The proposed HAI Action plan 2020 drives aggressive reductions in several 
categories of HAIs: 50% reduction in CLABSI from the 2015 baseline, 75% reduction in 
Staph from the 2007-2008 baseline, and 30% reduction in CDIFF from the 2015 baseline 
(ODPHP, 2015). Achieving the above results will require us to monitor and control both 
clinical and financial indicators in hospitals and specifically in the ICUs. Ongoing 
infection control efforts may need to target those categories of infections that are either 
the most prevalent and/or have the highest opportunity for improvement in reduction 
goals. For instance, results of this study have shown that CLABSI and CAUTI drive the 
highest HAI fold increase in LOS, followed by Staph and CDIFF. Likewise, the highest 
fold increase in mortality rate for patients in the ICU is associated with Sepsis, 
Pneumonia, CLABSI and CDIFF. Also, CLABSI, Pneumonia, Staph and Sepsis drive 





FIGURE 8: DISTRIBUTION OF HAI INFECTIONS IN THE ICU    
Out of the total number of 584,749 discharge records, an examination of the results lead 
us to the fact that Sepsis is the most coded form of infection in the ICU at 52% followed 
by Staph at 21%, CDIFF at 13%, Pneumonia at 10%, CLABSI at 3% and CAUTI at 1% 
(Figure 8). It needs to be noted that higher coding rates for sepsis could be a syndromic 
response to other infections and thus the reported infection types are not mutually 
exclusive. Per these distributions, hospital administrators, IP and ICU Directors may need 
to adopt appropriate and aggressive HAI control mechanisms in order to be able to 
achieve the best impact to their clinical and financial indicators and align with the 
national reduction goals as outlined in the HAI 2020 plan. For instance, while CLABSI, 
CAUTI and Pneumonia lead to higher fold increase in total cost and LOS for patients in 




(Figure 8). Likewise, average cost for patients in the ICU with CLABSI, CDIFF, CAUTI, 
or Pneumonia is $83,720 versus $75,787 for either Sepsis or Staph. However, the number 
of CLABSI and CAUTI infections in the ICU are not as high as other categories. Table 
18 summarizes the adjusted total cost incurred as a result of HAI type of infection in the 
ICU along with what would have been the associated costs in the ICU without the HAIs. 
By considering the total number of infections for each HAI type, the preventable costs 
can be computed as follows:  
Preventable costs = HAI infections in ICU for each type X (Difference in 












Sepsis $23,641  $72,122  27,107 $1,314,174,467  
Staph $24,625  $79,452  11,317 $620,477,159  
CDIFF $25,097  $66,782  6,973 $290,669,505  
Pneumonia $25,033  $96,326  5,107 $364,093,351  
CLABSI $25,380  $103,254  1,424 $110,892,576  






Total preventable costs: 
$2,729,517,818  
 
TABLE 18: PREVENTABLE ADJUSTED COSTS OF HAI IN ICU 
Examination of the summary of preventable costs in Table 18 for the four states of WA, 




opportunity to reduce costs in our healthcare system and this is in only four states over 
one year. Thus, it becomes imperative for us to explore reduction and elimination 
mechanisms for more prevalent HAI infections such as Sepsis and Staph that have higher 
preventable costs while aggressively pursuing reduction targets for CLABSI, CDIFF, 
CAUTI and Pneumonia per the proposed HAI 2020 reduction guidelines. Effectiveness 
of prior reduction control efforts in these HAI areas would also need to be examined so 
that it can be improved upon within the ICU. The study also sheds light that compared to 
whites, others and blacks (from a race perspective) have a higher mortality in ICU when 
infected with HAIs, especially when minorities make up a smaller percentage of 
admissions. This higher mortality rate among minorities may be a manifestation of 
existing both healthcare disparities and health disparities. The social and clinical 
dimensions of these observations may need to be further explored as it impacts the 
overall cost and mortality rates within the ICU.  
There are several important limitations to our study. First, the limitations of 
leveraging administrative data for surveillance and analysis is well known and 
established (Virnig & McBean, 2001). Administrative data from HCUP statewide 
databases may not capture all instances of HAI occurrences in an ICU and may not be as 
accurate as clinical records. Prior studies have leveraged HCUP data for analysis of HAI, 
but its effectiveness is dependent on coding and the related specificity and sensitivity 
(Glance, Stone, Mukamel & Dick, 2011). A study evaluated the Agency for Healthcare 
Research and Quality Patient Safety Indicators (PSIs) and cautioned that there could be 
under coding of certain HAIs in the administrative databases such as the HCUP. 




on the clinical and financial indicators in the ICU.  Second, we were not able to 
determine and capture all of the UTI and bloodstream infections that were a result of 
HAIs. Our effort to leverage ICD-9 diagnosis coding in HCUP statewide databases to 
identify additional cases of CAUTI or CLABSI as determined by UTIs caused by 
catheter usage or bloodstream infections caused by the usage of central lines did not yield 
substantial results. This is related to the limitation in how our databases such as HCUP do 
not fully represent the clinical condition of intervention versus what is appropriate for 
billing and administrative purposes. Third, while the study leveraged states (WA, FL, NY 
and NJ) that are geographically distributed and demographically different within the 
United States, the results are limited to the analysis of HCUP statewide data from 2012 
for these four states. It needs to be examined if inclusion of additional states and 
longitudinal analysis of data across multiple years yield a different result. Fourth, sepsis 
coding in the ICU, as stated earlier, could be a syndromic response to other infections, 
and thus this group may also include infections listed in the other infections group. Most 
importantly, all results from this study does not control for severity of illness so increases 
in risks associated with HAIs may, in part, be reflective of differences in severity 
between the HAI and no HAI groups. We would suggest that future studies in this area 
consider controlling for severity of illness in the ICU by using a newly developed Sepsis 
Severity Score for analysis of causation (Ford et al., 2016). Finally, our estimation of 
impact of HAIs on clinical and financial indicators may have an associated element of 
endogeneity. For instance, patients that have HAIs with longer LOS will have increased 
costs within the ICU. It is also a priori that patients with HAIs would be expected to have 




hospital administrators, IPs and ICU directors, the bias of this effect is lessened as 






Patient records from four HCUP Statewide Inpatient Databases (SID) for NJ, FL, NY and 
WA were examined using a Statistical Programming Tool (SAS) for association of HAIs 
to clinical and financial indications in the ICU. This study sheds important insights into 
how HAIs impact patients in the ICU and results demonstrate significant association 
between HAI in ICU to both clinical and financial indicators in all of the five hypotheses. 
It has been observed that significant association exists between all categories of HAIs and 
hospital LOS in patients who have had an ICU stay (9.20 days versus 22.95 days). 
Likewise, patients with HAI in ICU are 7.149 times more likely to die than those without 
HAI in the ICU. In addition, patients in the ICU with HAI were observed to have 3.02 
fold increase in total adjusted costs when compared to those that do not have HAI. 
 ICUs represent a growing and key component of cost in hospitals and continue to 
be a focal point for critical and palliative care. Patients within ICU have a high 
susceptibility to infections and HAIs represent a significant risk factor to their clinical 
and financial indicators. Given the significant impact of HAIs on LOS, mortality and 
total cost within ICU, appropriate infection control measures need to be adopted in order 





.Centers for Disease Control and Prevention. (2014, March 26). HAI Prevalence Study. 
Retrieved from http://www.cdc.gov/HAI/surveillance/index.html 
Denham, C. R., Angood, P., Berwick, D., Binder, L., Clancy, C. M., Corrigan, J. M. et al. 
(2009, December 1). Chasing Zero: Can Reality Meet the Rhetoric? Journal of 
Patient Safety, 5(4), 216-222. 
Ella, O., Svenja, S., Karolin, G., Frank, S., & Iris, F. C. (2013). The Prevalence of 
Nosocomial and Community Acquired Infections in a University Hospital. 
Institute for Medical Microbiology and Hospital Epidemiology, Hannover 
Medical School, 110(31-32), 533-540. DOI: 10.3238/arztebl.2013.0533 
Ford, D. W., Goodwin, A. J., Simpson, A. N., Johnson, E., Nadig, N., & Simpson, K. 
(2016). A Severe Sepsis Mortality Prediction Model and Score for Use with 
Administrative Data. Critical Care Medicine, 44, 319-327. 
Forster, D. H., Krause, G., Gastmeier, P., Ebner, W., Rath, A., Wischnewski, N. et al. 
(2000). Can quality circles improve hospital-acquired infection control? Journal 
of Hospital Infection, 45, 302-310. doi:10.1053/jhin.2000.0762 
Fukuda, H., Lee, J., & Imanaka, Y. (2011, October). Variations in analytical 
methodology for estimating costs of hospital-acquired infections: A systematic 
review. The Hospital Infection Society, 77, 93-105. 
doi:10.1016/j.jhin.2010.10.006 
Glance, L. G., Stone, P. W., Mukamel, D. B., & Dick, A. W. (2011, March 21). Increases 
in Mortality, Length of Stay, and Cost Associated With Hospital-Acquired 




Jain, M., Miller, L., Belt, D., King, D., & Berwick, D. M. (2006, April 15). Decline in 
ICU adverse events, nosocomial infections and cost through a quality 
improvement initiative focusing on teamwork and culture change. Quality Safety 
Health Care, 15, 235-239. doi: 10.1136/qshc.2005.016576 
Kaye, K. S., Marchaim, D., Chen, T.-Y., Baures, T., Anderson, D. J., Choi, Y. et al. 
(2014, February). Effect of Nosocomial Bloodstream Infections on Mortality, 
Length of Stay, and Hospital Costs in Older Adults. Journal American Geriatrics 
Society, 62(2), 306-311. DOI: 10.1111/jgs.12634 
Leiyu, S. (2008). Health Services Research Methods. Clifton Park, NY: Delmar Cengage 
Learning. 
Medscape. (2001). Feeding Back Surveillance Data To Prevent Hospital-Acquired 
Infections [Emerging Infectious Diseases]. Retrieved from 
http://www.medscape.com/viewarticle/414409_4 
Necla, D., Esra, O., Semih, D., Saziye, S., & Filiz, K. (2013, March 20). Three-Year 
Evaluation of Nosocomial Infection Rates of the ICU. REVISTA BRASILEIRA DE 
ANESTESIOLOGIA, 63(1), 73-84. 
ODPHP. (2015, April 5). Office of Disease Prevention and Health Promotion. Retrieved 
from http://odphp.hhs.gov/ 
Pittoni, G. M., & Scatto, A. (2009). Economics and outcome in intensive care unit. 
Current Opinion in Anesthesiology, 22, 232-236. 
Plowman, R., Graves, N., M.A. S. Griffin, M., Roberts, J., Swan, A., Cookson, B. et al. 
(2001). The rate and cost of hospital-acquired infections occurring in patients 




national burden imposed. Journal of Hospital Infection, 47, 198-209. 
doi:10.1053/jhin.2000.0881 
Romano, P. S., Mull, H. J., Rivard, P. E., Zhao, S., Henderson, W. G., Loveland, S. et al. 
(2009, February). Validity of Selected AHRQ Patient Safety Indicators Based on 
VA National Surgical Quality Improvement Program Data. Health Services 
Research, 44(12), 182-204. 
Shannon, R. P. (2011). Eliminating catheter-associated urinary tract infections in the 
intensive care unit: is it an attainable goal? The American Clinical and 
Climatological Association, 122, 103-114. 
Sheng, W., Wang, J., Lu, D., Chie, W., Chen, Y., & Chang, S. (2005, January). 
Comparative impact of hospital-acquired infections on medical costs, length of 
hospital stay and outcome between community hospitals and medical centres. 
Journal of Hospital Infection, 59, 205-214. 
U.S. Department of HHS. (2014, July 26). HAI action plan. Retrieved from 
http://www.health.gov/hai/prevent_hai.asp 
US HHS. (2015, January). HAI action plan 2020. Retrieved from 
http://www.health.gov/hai/pdfs/HAI-Targets.pdf 
Virnig, B. A., & McBean, M. (2001). Administrative Data for Public Health Surveillance 
and Planning. Annual Review Public Health, 22, 213-230. 
Vrijens, F., Hulstaert, F., VandeSande, S., Devriese, S., Morales, I., & Parmentier, Y. 
(2010, April). Hospital-acquired, laboratory-confirmed bloodstream infections: 
Linking national surveillance data to clinical and financial hospital data to 




Infection, 75, 158-162. doi:10.1016/j.jhin.2009.12.006 
Wilcox, M., Cunniffe, J., Trundle, C., & Redpath, C. (1996, March). Financial burden of 
hospital-acquired Clostridium difficile infection. Journal of Hospital Infection, 
34, 23-30. 
Wilcox, M., & Dave, J. (2000a). The cost of hospital-acquired infection and the value of 











HCUP State Inpatient Databases (SID) availability of data elements 
Central Distributor 
SID Availability of Data Elements by year - 2013.pdf
 
HCUP Statistical Brief describing ICU data 







Appendix B – Search Results Summary 
Below table summarizes the broader taxonomy of these literature search results. 
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Appendix C – Data Dictionary and Limitations 
 
Field Data Type Values Description 
ADATE YYMMDD Missing (.), Invalid 
(.A, .B or .C) 
 
Admission date. To protect privacy, 
replaced by AMONTH and 
AYEAR 
AGE Number Missing (.), Invalid 
(.A, .B, .C) 
Age in years (AGE) is calculated 
from the birth date (DOB) and the 
admission date (ADATE) in the 
HCUP State databases 
ATYPE Integer 1 = Emergency, 2 = 
Urgent, 3 = 
Elective, 4 = 
Newborn, 5 = 
Delivery or 
Trauma, 6 = Other, 
Missing (.), Invalid 
(.A, .B) 
ATYPE indicates the type of 
admission (emergency, urgent, 
elective, etc.) 
DDATE MMDDYY Missing (.), Invalid 
(.A, .B or .C) 
Date of discharge 
DIED Number 0 if patient was 
discharged alive, 1 
Died during hospitalization (DIED) 




Field Data Type Values Description 
if patient died in 
the hospital, 
missing (., .A) 
disposition of patient 
DOB MMDDYY Missing (.), Invalid 
(.A, .B or .C) 
 
Admission date. To protect privacy, 
replaced by AMONTH and 
AYEAR 
DRG Character ICD-9-CM 
character coding 
Diagnosis Related Group (DRG) 
appropriate for the date of 
discharge is assigned by the 
Medicare DRG Grouper 





= exempt from 
POA reporting, 
Blank = acceptable 
value on diagnosis 
exempt from POA 
reporting 
DXPOAn indicates whether each 
diagnosis (DXn) was present at 
admission. This provides an 
indicator of complications arising 
during a hospitalization. The coding 
of this data element is consistent 
with the UB-04 standards. No edits 
checks are performed on this data 




Field Data Type Values Description 
DaysCCU Number Missing (.), Invalid 
(.A) 
Days in the coronary care unit  
DaysICU Number Missing (.), Invalid 
(.A) 
Days in the intensive care unit  
DaysNICU Number Missing (.), Invalid 
(.A) 
Days in the neonatal care unit  
DaysPICU Number Missing (.), Invalid 
(.A) 
Days in the pediatric care unit  





Unique HCUP hospital identifier 
IDNUMBER Character 6(n), missing 
(blank) 
Modified AHA ID number 
LOS Number 0-365, Missing (.), 
Invalid (.A, .B, .C) 
Length of stay (LOS) is calculated 
by subtracting the admission date 






















pay, 5=no charge, 
6=other, Missing 
(.), Invalid (.A, .B) 
PAY1 indicates the expected 
primary payer (Medicare, 
Medicaid, private insurance, etc.) 
PSTATE Character aa, Missing (blank) Two character state postal code 
RACE Number 1=White, 2=Black, 
3=Hispanic, 








Field Data Type Values Description 
(.), Invalid (.A, .B) 
SEX Number 1=Male, 2=Female, 
Missing (.), Invalid 
(.A, .B, .C) 
Sex of the patient 
TOTCHG Character Dollars, Missing 
(.), Invalid (.A, .B, 
.C) 
Total edited charges  with values 
rounded to the nearest dollar 
U_CCU Number 0=service is not 
reported on record, 
> 0 – service 
reported  
Utilization flag for Coronary Care 
Unit (CCU) includes medical care 
provided to patients with coronary 
illness who require a more intensive 
level of care than is rendered in the 
general medical unit 
U_ICU Number 0=service is not 
reported on record, 
> 0 – service 
reported 
Utilization flag for Intensive Care 
Unit (ICU) includes medical care 
provided to patients who require a 
more intensive level of care than is 
rendered in the general medical unit 
YEAR YY or 
YYYY 
2 digit or 4 digit Discharge year for the patient 
















Appendix D – Summary of Results (Data Files) 
 
Summary of results 
- NJ
 
Summary of results 
- FL
 
Summary of results 
- FL
 







Appendix E – Patient Descriptive Statistics Results 
 
Table of State by Any_Clear_HAI 
State Any_Clear_HAI 
Frequency 

























Total 543020 41729 584749 
 
 
Statistics for Table of State by Any_Clear_HAI 
 













Phi Coefficient  0.1724  
Contingency Coefficient  0.1699  
Cramer's V  0.1724  
 










Table of State by SepsisHAI 
State SepsisHAI 
Frequency 



































Statistics for Table of State by SepsisHAI 
 













Phi Coefficient  0.1691  
 
 
Statistic DF Value Prob 
Contingency Coefficient  0.1667  
Cramer's V  0.1691  
 
Sample Size = 584749 
 
 
Table of State by BacterimiaHAI 
State BacterimiaHAI 
Frequency 

























Total 582053 2696 584749 
 
 
Statistics for Table of State by BacterimiaHAI 
 













Phi Coefficient  0.0345  
Contingency Coefficient  0.0345  
Cramer's V  0.0345  
 







Table of State by CLABSIHAI 
State CLABSIHAI 
Frequency 

























Total 583325 1424 584749 
 
 
Statistics for Table of State by CLABSIHAI 
 













Phi Coefficient  0.002
5 
 
Contingency Coefficient  0.002
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Table of State by UTIHAI 
State UTIHAI 
Frequency 



































Statistics for Table of State by UTIHAI 
 













Phi Coefficient  0.1390  
Contingency Coefficient  0.1377  
Cramer's V  0.1390  
 






Table of State by CAUTIHAI 
State CAUTIHAI 
Frequency 
































Statistics for Table of State by CAUTIHAI 
 













Phi Coefficient  0.0294  
Contingency Coefficient  0.0294  
Cramer's V  0.0294  
 






Table of State by PNEUMONIAHAI 
State PNEUMONIAHAI 
Frequency 

























Total 579642 5107 584749 
 
 
Statistics for Table of State by PNEUMONIAHAI 
 













Phi Coefficient  0.0504  
Contingency Coefficient  0.0504  
Cramer's V  0.0504  
 







Table of State by StaphHAI 
State StaphHAI 
Frequency 



































Statistics for Table of State by StaphHAI 
 













Phi Coefficient  0.0702  
Contingency Coefficient  0.0700  
Cramer's V  0.0702  
 






Table of State by CDIFFHAI 
State CDIFFHAI 
Frequency 



































Statistics for Table of State by CDIFFHAI 
 













Phi Coefficient  0.0444  
Contingency Coefficient  0.0443  
Cramer's V  0.0444  
 





Table of FEMALE by Any_Clear_HAI 
FEMALE(Indicator 
of sex) Any_Clear_HAI 
Frequency 













Total 543016 41729 584745 
Frequency Missing = 4 
 
 
Statistics for Table of FEMALE by Any_Clear_HAI 
 

















Phi Coefficient  -0.0191  
Contingency Coefficient  0.0191  






Fisher's Exact Test 
Cell (1,1) Frequency (F) 268414 
Left-sided Pr <= F 1.941E-
48 
Right-sided Pr >= F 1.0000 
  
Table Probability (P) 2.686E-
49 
Two-sided Pr <= P 3.771E-
48 
 
Effective Sample Size = 584745 
Frequency Missing = 4 
 
 
Table of new_race by Any_Clear_HAI 
new_race Any_Clear_HAI 
Frequency 

























Total 543020 41729 584749 
 
 
Statistics for Table of new_race by Any_Clear_HAI 
 
The SAS System 
The FREQ Procedure  





 80  
 













Phi Coefficient  0.0358  
Contingency Coefficient  0.0358  
Cramer's V  0.0358  
 
























Total 543019 41728 584747 
Frequency Missing = 2 
 
 
Statistics for Table of DIED by Any_Clear_HAI 
 

















Phi Coefficient  0.2059  
Contingency Coefficient  0.2017  






Fisher's Exact Test 
Cell (1,1) Frequency (F) 52321
9 
Left-sided Pr <= F 1.000
0 
Right-sided Pr >= F 0.000
0 
  
Table Probability (P) 0.000
0 
Two-sided Pr <= P 0.000
0 
 
Effective Sample Size = 584747 
Frequency Missing = 2 
 
 



































Total 542919 41717 584636 
Frequency Missing = 113 
 
 














Mantel-Haenszel Chi-Square 1 4.6141 0.031
7 
Phi Coefficient  0.0267  
Contingency Coefficient  0.0267  
Cramer's V  0.0267  
 
Effective Sample Size = 584636 
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0.0918 0 111.0 




0.1033   
 
 
Any_Clear_HAI Method Mean 95% CL Mean Std Dev 












































   
 
 




Satterthwaite Unequal 49673 -2.98 0.0029 
 
 
Equality of Variances 
Method Num DF Den DF F Value Pr > F 



































Any_Clear_HAI Method Mean 
95% CL 
Mean Std Dev 












































   
 
 









Equality of Variances 
Method Num DF Den DF F Value Pr > F 













Any_Clear_HAI N Mean Std Dev Std Err Minimum Maximum 
0 54302
0 





0.1169 4.0000 359.0 









HAI Method Mean 95% CL Mean Std Dev 
95% CL Std 
Dev 

















Diff (1-2) Satterthwaite -13.4387 -13.6687 -
13.2
086 
   
 
 













Equality of Variances 
Method Num DF Den DF F Value Pr > F 



















134.9 919.0 4718378 
1 41724 24247
8 
273460 1338.8 5609.0 4775864 
Diff (1-2)  -
14693
6 




_HAI Method Mean 95% CL Mean 
Std De
v 
95% CL Std 
Dev 


































   
 
 













Equality of Variances 
Method Num DF Den DF F Value Pr > F 




























393.3 3628.8 1433495 





163.4   
 
 
Any_Clear_HAI Method Mean 95% CL Mean Std Dev 


















































   
 
 













Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 31875 507152 9.11 <.000
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